Last reviewed · How we verify
NCT05239988: RECOVER
Observational Study in COVID-19 Patients Treated With Remdesivir
trial testing no experimental intervention in Hospitalization in 1,004 participants. Completed in 30 June 2022.
30 June 2022
Quick facts
| Lead sponsor | Fadoi Foundation, Italy |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 1,004 |
| Start date | 24 November 2021 |
| Primary completion | 30 June 2022 |
| Estimated completion | 30 June 2022 |
| Sites | 30 locations across Italy |
Drugs / interventions tested
- no experimental intervention
Conditions studied
- Hospitalization — all drugs for Hospitalization →
Sponsor
Fadoi Foundation, Italy
Who can join
18 and older, any sex, with Hospitalization. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Taking into account the high number of COVID-19 patients managed in Italian Internal Medicine, Fadoi Foundation (Italian Scientific Society of Internal Medicine) promotes a national retrospective observational study in patients treated with Remdesivir, analyzing the characteristics of patients and their clinical outcome during hospitalization, and thus providing real-life information potentially useful to integrate the evidence produced by studies conducted under experimental conditions and available in the literature.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05239988
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of no experimental intervention
Trials testing the same drug.
- NCT05247060 — Orthostatic Hypotension in Hypertensive Patient Hospitalized in Internal Medicine · completed
Other recruiting trials for Hospitalization
Currently open trials in the same condition.
- NCT07173114 — New Approaches for Evaluating the Interchangeability of Reference Materials and Quality Controls (COMET-MPL) · recruiting
- NCT05522647 — Detection of Risk Behaviors: Pilot Observational Study With Bedridden and Agitated Patients. · recruiting
- NCT06579950 — Assessing the Effects of Cool Roofs on Indoor Environments and Health · NA · recruiting
- NCT06865781 — Vital Signs Reduction Study · NA · active not recruiting
- NCT06519253 — Virtual Reality Music in Geriatric Inpatients · NA · recruiting
Other Fadoi Foundation, Italy trials
Trials by the same sponsor.
- NCT05247931 — Why Does Aspirin Fail in Secondary Cerebrovascular Prevention? A Multicenter Prospective Case - Control Study · unknown
- NCT04257422 — Intentional Rounding in Internal Medicine · NA · terminated
- NCT06293768 — Continuous Wireless Monitoring for Patients in the Internal Medicine UOC. Randomized Controlled Trial (GreenLineH-T) · NA · completed
- NCT04589533 — MANAGEMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS HOSPITALIZED IN INTERNAL MEDICINE UNITS (MINDER Study) · unknown
- NCT04267718 — Efficacy of the Use of Risk Scores in Reducing Important Clinical Outcomes in Hospitalized Medical Ill Patients · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05239988 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fadoi Foundation, Italy
- Last refreshed: 28 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05239988.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing